Friday, December 6, 2024, San Diego, California, 11:30 AM – 1:30 PM PT (2:30 PM – 4:30 PM ET)
What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma
A CME Friday Satellite Symposium and Webcast Preceding the 66th ASH Annual Meeting
Event Details
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting
Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California
Meeting Room
Seaport A-D (Second Level)
Jennifer Crombie, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Martin Hutchings, MD, PhD
Senior Consultant
Department of Haematology and Phase 1 Unit
Rigshospitalet, Copenhagen University Hospital
Professor of Clinical Lymphoma Research
Department of Clinical Medicine
University of Copenhagen
Copenhagen, Denmark
Matthew Lunning, DO
Associate Professor of Medicine
Medical Director, Cellular Therapy
Associate Vice Chair of Research
Assistant Vice Chancellor for Clinical Research
Division of Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska
Tycel Phillips, MD
Associate Professor, Division of Lymphoma
Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
Duarte, California
Moderator
Jeremy S Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Regeneron Pharmaceuticals Inc.
Agenda
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting
MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson
- Factors influencing patient eligibility for CAR T-cell therapy, such as age, performance status, comorbidities and prior therapies
- Long-term efficacy and safety data with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for multiregimen-relapsed DLBCL
- Major findings from Phase III studies of CAR T-cell therapy as second-line treatment for DLBCL
- FDA approvals of axi-cel and liso-cel as second-line therapy and identification of candidates for this strategy
- Available data (eg, from the ZUMA-12 trial) and ongoing research with CAR T-cell therapy in the up-front setting
- Early results with and ongoing investigation of other CAR T-cell platforms in the treatment of DLBCL
MODULE 2: Bispecific Antibody Therapy for DLBCL — Prof Hutchings
- Mechanistic similarities and differences among the various bispecific antibodies targeting CD20 and CD3 in non-Hodgkin lymphoma (NHL); implications for efficacy, tolerability and ease of use
- Key outcomes from pivotal studies of glofitamab and epcoritamab monotherapy for relapsed/refractory (R/R) DLBCL
- FDA approvals of glofitamab and epcoritamab for R/R DLBCL; optimal selection and sequencing of these agents
- Updated data from the Phase I ELM-1 and pivotal Phase II ELM-2 studies of odronextamab for R/R DLBCL
- Current regulatory status and ongoing Phase III evaluation of odronextamab in DLBCL
- Recently presented findings from the Phase III STARGLO study evaluating glofitamab in combination with gemcitabine and oxaliplatin (GemOx) versus rituximab and GemOx for patients with R/R DLBCL
MODULE 3: CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning
- Principal outcomes with axi-cel, tis-cel and liso-cel for R/R follicular lymphoma (FL)
- Selection of appropriate candidates with R/R FL for CAR T-cell therapy
- Key clinical research findings with brexucabtagene autoleucel and liso-cel for R/R mantle cell lymphoma (MCL)
- Optimal integration of CAR T-cell therapy into current MCL treatment
MODULE 4: Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes — Dr Phillips
- Available data with mosunetuzumab and epcoritamab monotherapy for patients with R/R FL
- FDA approvals of mosunetuzumab and epcoritamab for R/R FL; optimal sequencing relative to other available treatment options
- Documented antitumor activity of other bispecific antibodies, such as odronextamab, in patients with FL
- Early data with and ongoing evaluation of bispecific antibodies in combination with other systemic therapies for R/R FL
- Available data with, ongoing investigation of and potential clinical role for bispecific antibodies for other NHL subtypes
MODULE 5: Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie
- Comparative frequency and severity of cytokine release syndrome (CRS) and neurotoxicity with anti-CD19 CAR T-cell constructs available for various NHL subtypes; optimal monitoring and management
- Long-term tolerability and toxicity considerations with CAR T-cell therapy, such as delayed neurotoxicity, cytopenias, hypogammaglobulinemia and infection
- FDA investigation of the risk of T-cell cancers for patients who have received CAR T-cell therapy; FDA-mandated boxed warning
- Incidence, severity and time course of CRS and neurotoxicity with bispecific antibody therapy for patients with NHL
- Other tolerability concerns with bispecific antibodies for NHL; recommended mitigation and management protocols
CE Information
Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to
- Understand the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of non-Hodgkin lymphoma (NHL).
- Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies in patients with various forms of NHL, and assess the similarities and differences among currently available and investigational agents in this class.
- Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma, and optimally incorporate these approaches into treatment algorithms.
- Assess available research findings with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for other B-cell lymphomas, including follicular lymphoma and mantle cell lymphoma, and identify patients for whom these approaches should be considered or recommended.
- Recognize adverse events associated with available and investigational CAR T-cell therapies and bispecific antibodies, and implement strategies to educate patients and manage complications.
- Recall ongoing research attempting to further define the optimal role of CAR T-cell therapy and bispecific antibody-based strategies for NHL, and appropriately counsel patients about clinical trial participation.
CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Crombie — Advisory Committees: AbbVie Inc, ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Consulting Agreement: Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Merck. Prof Hutchings — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genmab US Inc, Janssen Biotech Inc, Merck, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genmab US Inc, Roche Laboratories Inc. Dr Lunning — Consulting Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, CRISPR Therapeutics, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Recordati, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Vittoria Biotherapeutics; Research Funding: Bristol Myers Squibb, Fate Therapeutics, Sana Biotechnology. Dr Phillips — Advisory Committees: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Merck; Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol Myers Squibb, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, TG Therapeutics Inc; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group; Steering Committee: Genentech, a member of the Roche Group.
MODERATOR — Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Cellectar Biosciences Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Interius BioTherapeutics, Janssen Biotech Inc, Lilly, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.
Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Regeneron Pharmaceuticals Inc.
Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Meeting Room
Seaport A-D (Second Level)
Registration
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.
Manchester Grand Hyatt is conveniently located 10 minutes (0.5 mile) walking distance from the San Diego Convention Center, where the 66th ASH Annual Meeting is taking place.
If you have any questions, please feel free to contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting and Exposition.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.